中国造埃博拉药物挽救生命却卷入专利纠纷_时事

中国造埃博拉药物挽救生命却卷入专利纠纷

The London hospital has since decided not to join the American-run clinical trial of ZMappbecause of the randomizing requirement. It has opted instead to keep a supply of MIL77 foruse in any Ebola patients treated in Britain or the European Union.

这家伦敦医院因此决定不加入由美国进行的Zmapp临床测试，原因是其随机化的要求。作为代替，其决定保持MIL77的供应，用以所有英国和欧盟内的埃博拉病人的治疗。

“We’ve challenged ourselves about whether that is the right decision or not, Dr. Jacobs said. “In the end, I have to do my best for the patient in front of me.

“我们已经在这是否是个正确决定的问题上质疑了自己，雅各布博士说，“最后，我必须为我面前的病人做到最好。

But Dr. H. Clifford Lane, clinical director at the National Institute of Allergy and InfectiousDiseases, said it was important to test ZMapp properly to determine whether using antibodiesto treat Ebola really works.

但是国家过敏和传染病研究所(National Institute of Allergy and Infectious Diseases)临床主任克利福德·莱恩博士(Clifford Lane)表示，用合适的手段测试ZMapp以确定使用抗体治疗埃博拉是否有效是至关重要的。

“There are interventions that look so logical, that should be effective, that prove not to be,he said. “Without randomization, you have no way to control for all the different variables thatcome into play when you’re dealing with a patient.